Abstract 923P
Background
Targeting the PD1/PD-L1 axis in head and neck squamous cell carcinoma (HNSCC) patients improves survival. However, only a minority of patients (pts) respond to treatment. Preclinical data suggests that vorinostat (V), an HDAC inhibitor, might improve immunotherapy efficacy by modulating the epigenome.
Methods
PEVOsq is an open-label, non-randomized, multi-center, basket phase II trial, evaluating the efficacy of pembrolizumab (P) in combination with V in pts with recurrent and/or metastatic squamous carcinomas. Pts had to be PD1/PD-L1 antagonist-naïve with no restriction in terms of prior lines of treatments. P dose was 200 mg Q3W IV, and V 400 mg QD PO. A’Hern design with the following hypotheses (alpha=5%, power=90%, p0=10%, p1=35%). Primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), and duration of response (DOR).
Results
Among 112 included pts, 27 and 26 HNSCC pts were evaluable for safety and efficacy. Median age was 59 years old [range: 18-77]. Median number of prior lines of therapies was 0 [range: 0-1]. Five pts (19.2%, [95%CI: 6.6-39.4]) had an objective response. Median DOR was 3.2 months [95%CI: 1.3-NR]. Median PFS and OS were 4.1 [95%CI: 1.5-4.4] and 9.2 months [95%CI: 6.8-14.4], respectively. Ten pts (37.0%) developed G3/4 treatment related adverse events. P and V were stopped for toxicity in 3.8% and 30.8% of pts, respectively. 40.7% of pts had a dose-reduced of V for toxicity including hematotoxicity, gastrointestinal toxicity, asthenia, and creatinine increase. Results according to PDL1, MSI, TMB and HPV will be presented at the meeting.
Conclusions
P combined with V produced encouraging antitumor activity in HNSCC pts independant of PD-L1 expression, although the V dose had to be reduced in a substantial proportion of pts.
Clinical trial identification
NCT04357873, EudraCT 2019-003839-33.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
ERAPerMED ANR Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12